These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 11050808

  • 21. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP, Arnulf I, Demeret S, Damier P, Bonnet AM, Houeto JL, Agid Y.
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [Abstract] [Full Text] [Related]

  • 22. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 23. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 24. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
    Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, Juncos JL, Maragoto C, Guridi J, Litvan I, Tolosa ES, Koller W, Vitek J, DeLong MR, Obeso JA.
    Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
    [Abstract] [Full Text] [Related]

  • 25. Isoniazid therapy in Parkinson's disease.
    Gershanik OS, Luquin MR, Scipioni O, Obeso JA.
    Mov Disord; 1988 Mar; 3(2):133-9. PubMed ID: 3221901
    [Abstract] [Full Text] [Related]

  • 26. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

  • 27. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN.
    Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
    [Abstract] [Full Text] [Related]

  • 28. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H.
    Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088
    [Abstract] [Full Text] [Related]

  • 29. Motor complications in Parkinson's disease: ten year follow-up study.
    López IC, Ruiz PJ, Del Pozo SV, Bernardos VS.
    Mov Disord; 2010 Dec 15; 25(16):2735-9. PubMed ID: 20931632
    [Abstract] [Full Text] [Related]

  • 30. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug 15; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 31. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 15; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

  • 32. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y, Filiano JJ, Kish SJ.
    Mov Disord; 2004 Oct 15; 19(10):1256-8. PubMed ID: 15389992
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, NS-Park CIC Network.
    Neurology; 2014 Jan 28; 82(4):300-7. PubMed ID: 24371304
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P, Konitsiotis S, Tagaris G, Peterson D, VALID-PD Study Group.
    Mov Disord; 2011 Feb 01; 26(2):264-70. PubMed ID: 21412833
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J, Ibáñez R, Gudín M, Hernández A.
    Neurologia; 2003 Apr 01; 18(3):162-5. PubMed ID: 12677484
    [Abstract] [Full Text] [Related]

  • 40. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov 01; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.